Gensci Showcases BsADC Pipeline at 4th World ADC Asia Summit

Time

2025-06-17

Readership

Gensci presented its innovative Bispecific ADC portfolio at the 4th World ADC Asia Summit in Incheon, Korea on June 10. John L. Xu, Executive VP, Discovery Research in Immunology and Oncology of GenSci, showcased its cutting-edge oncology pipeline to global peers.

John L. Xu was delivering a keynote speech

At the conference, Dr. Xu delivered a keynote speech titled "Bispecific ADCs for Targeted Cancer Therapy." He introduced three novel ADC candidates, all featuring dual-target/biparatopic designs: GenSci143 (B7-H3 x PSMA), GenSci139 (EGFR x HER2), and GenSci140 (FRα biparatopic). These projects demonstrate highly differentiated target selection and mechanisms of action, indicating promising development potential.

Dr. Xu emphasized that Gensci's differentiation strategy centers on optimized linker and payload combinations. The proprietary linkers used exhibit high hydrophilicity and stability. They remain largely intact in the bloodstream and healthy tissues, minimizing off-target toxicity from premature payload release. However, the linkers rapidly cleave within tumor cells after ADC internalization, efficiently releasing the payload. All three projects utilize the same topoisomerase I inhibitor payload, GSC5181. This payload demonstrates enhanced DNA-damaging activity for potent tumor cell killing. Preclinical data also shows favorable cell membrane permeability and rapid systemic clearance for GSC5181, enabling effective and safe bystander killing effects.

John L. Xu's keynote presentation

Compared to relevant single-target ADC competitors, our three bispecific ADC candidates show superior anti-tumor activity and a wider therapeutic window in preclinical studies," stated Dr. Xu. "This potential for Best-in-Class (BIC) differentiation stems from our unique bispecific antibody designs and optimized linker/payload combinations. We look forward to establishing deep strategic partnerships with leading MNCs. Collaborating on innovative molecules will enhance the clinical translation efficiency of our pipeline and accelerate commercialization, ultimately bringing these novel therapies to patients worldwide faster."

Gensci's participation highlighted the vibrant innovation of Chinese biopharma in the ADC field at this global forum. The company remains committed to advancing oncology research to deliver more breakthrough treatment options for patients globally.